-
Mashup Score: 0
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Momelotinib Improves Anemia in JAK Inhibitor-Naive Myelofibrosis - 7 hour(s) ago
Compared with ruxolitinib, momelotinib improved mild, moderate, and severe anemia in patients with myelofibrosis who were naive to JAK inhibitors, according to the phase 3 SIMPLIFY-1 study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma - 10 hour(s) ago
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19MW2821 Gains FDA Orphan Drug Designation in Esophageal Cancer - 12 hour(s) ago
9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other cancers.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Understanding the Deep Response to Pacritinib in Myelofibrosis - 14 hour(s) ago
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the deep response with pacritinib and its adverse event profile for patients with myelofibrosis in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Patient Case 1: Patient with Intermediate Risk Myelofibrosis - 15 hour(s) ago
Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment with ruxolitinib has been initiated.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Real-world data suggests similar survival for patients with metastatic kidney cancer receiving cabozantinib with or without a PD-L1 inhibitor after prior PD-L1 treatment. #KCSM | @umangtalking @huntsmancancer https://t.co/Y0Ic5u795O